Mustang Bio Inc. (MBIO) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Mustang Bio Inc. (MBIO)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

0.13

-0.01 (-9.60%)

At close: Jan 15, 2025, 11:41 AM

undefined% (undefined)

Bid	0.13
Market Cap	6.28M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-1.33
PE Ratio (ttm)	-0.1
Forward PE	n/a
Analyst	Buy

Ask	0.13
Volume	5,678,323
Avg. Volume (20D)	9,047,472
Open	0.13
Previous Close	0.14
Day's Range	0.11 - 0.15
52-Week Range	0.11 - 1.52
Beta	undefined

About MBIO

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develo...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Aug 22, 2017

Employees 80

Stock Exchange NASDAQ

Ticker Symbol MBIO

Website https://www.mustangbio.com

Analyst Forecast

According to 1 analyst ratings, the average rating for MBIO stock is "Buy." The 12-month stock price forecast is $2, which is an increase of 1452.80% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

1 day ago · Source New

-35.77%

Mustang Bio shares are trading lower after the com... Unlock content with Pro Subscription

6 months ago · Source

Mustang Bio shares are trading lower after the company announced a $2.5 million registered direct offering of 6.130 million shares at $0.41 per share.

News

7 months ago · zacks.com

Mustang (MBIO) Soars 477% on Data From Rare Blood Cancer Study

Updated data from a clinical study shows that treatment with Mustang Bio's (MBIO) experimental cell therapy achieved an overall response rate of 90% in patients with a rare form of blood cancer.

7 months ago · invezz.com

Why are Mustang Bio shares (MBIO) up almost 500%?

The Mustang Bio stock price closed on a high yesterday, trading at $0.75. The pharmaceutical company has gone vertical in the past 24 hours, climbing 476.9% to go from $0.13 to $0.75 in a single day.

7 months ago · benzinga.com

Crude Oil Rises 1%; Mustang Bio Shares Spike Higher

U.S. stocks traded mixed midway through trading, with the S&P 500 edging higher on Monday.

7 months ago · investorplace.com

Why Is Mustang Bio (MBIO) Stock Up 347% Today?

Mustang Bio (NASDAQ: MBIO ) stock is taking off on Monday after the clinical-stage biopharmaceutical company announced positive results from a study. The recent news includes favorable results from th...

7 months ago · benzinga.com

Why Is Penny Stock Mustang Bio Trading Over 190% On Monday?

Penny stock Mustang Bio Inc MBIO shares are trading higher on a strong session volume of 90 million versus an average volume of 3.17 million, as per data from Benzinga Pro.

7 months ago · investorplace.com

Why Is Mustang Bio (MBIO) Stock Up 58% Today?

Mustang Bio (NASDAQ: MBIO ) stock is taking off on Wednesday alongside heavy pre-market trading of the clinical-stage biopharmaceutical company's shares. This has more than 13.9 million shares of MBIO...

8 months ago · https://www.defenseworld.net

HC Wainwright Analysts Lower Earnings Estimates for Mustang Bio, Inc. (NASDAQ:MBIO)

Mustang Bio, Inc. (NASDAQ:MBIO – Free Report) – Analysts at HC Wainwright reduced their Q2 2024 earnings estimates for Mustang Bio in a research note issued to investors on Thursday, May 1...